These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37595816)

  • 1. Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies.
    Bollack A; Markiewicz PJ; Wink AM; Prosser L; Lilja J; Bourgeat P; Schott JM; Coath W; Collij LE; Pemberton HG; Farrar G; Barkhof F; Cash DM;
    Neuroimage; 2023 Oct; 280():120313. PubMed ID: 37595816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.
    Bourgeat P; Doré V; Burnham SC; Benzinger T; Tosun D; Li S; Goyal M; LaMontagne P; Jin L; Rowe CC; Weiner MW; Morris JC; Masters CL; Fripp J; Villemagne VL;
    Neuroimage; 2022 Nov; 262():119527. PubMed ID: 35917917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of regional brain amyloid-β deposition with
    Bao YW; Wang ZJ; Guo LL; Bai GJ; Feng Y; Zhao GD
    Neuroradiology; 2024 Sep; 66(9):1537-1551. PubMed ID: 38676749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses.
    Ruwanpathirana GP; Williams RC; Masters CL; Rowe CC; Johnston LA; Davey CE
    J Nucl Med; 2024 May; 65(5):781-787. PubMed ID: 38575189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.
    Jovalekic A; Roé-Vellvé N; Koglin N; Quintana ML; Nelson A; Diemling M; Lilja J; Gómez-González JP; Doré V; Bourgeat P; Whittington A; Gunn R; Stephens AW; Bullich S
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3276-3289. PubMed ID: 37300571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies.
    Bourgeat P; Doré V; Doecke J; Ames D; Masters CL; Rowe CC; Fripp J; Villemagne VL;
    Neuroimage; 2021 Feb; 226():117593. PubMed ID: 33248259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
    J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing the centiloid transformation for
    Bourgeat P; Doré V; Fripp J; Ames D; Masters CL; Salvado O; Villemagne VL; Rowe CC;
    Neuroimage; 2018 Dec; 183():387-393. PubMed ID: 30130643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A universal neocortical mask for Centiloid quantification.
    Bourgeat P; Doré V; Rowe CC; Benzinger T; Tosun D; Goyal MS; LaMontagne P; Jin L; Weiner MW; Masters CL; Fripp J; Villemagne VL; ;
    Alzheimers Dement (Amst); 2023; 15(3):e12457. PubMed ID: 37492802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of [
    Golla SS; Verfaillie SC; Boellaard R; Adriaanse SM; Zwan MD; Schuit RC; Timmers T; Groot C; Schober P; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BN; Lammertsma AA
    J Cereb Blood Flow Metab; 2019 Nov; 39(11):2172-2180. PubMed ID: 29897009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
    Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
    J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
    Asken BM; Elahi FM; La Joie R; Strom A; Staffaroni AM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Karydas A; Wang P; Rojas JC; Boxer AL; Miller BL; Rabinovici GD; Kramer JH; Casaletto KB
    J Alzheimers Dis; 2020; 78(1):265-276. PubMed ID: 32986672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
    Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
    Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.
    Leuzy A; Lilja J; Buckley CJ; Ossenkoppele R; Palmqvist S; Battle M; Farrar G; Thal DR; Janelidze S; Stomrud E; Strandberg O; Smith R; Hansson O
    Neurology; 2020 Nov; 95(21):e2834-e2844. PubMed ID: 33077542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale.
    de Souza GS; Andrade MA; Borelli WV; Schilling LP; Matushita CS; Portuguez MW; da Costa JC; Marques da Silva AM
    Mol Imaging Biol; 2022 Jun; 24(3):394-403. PubMed ID: 34611766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.